Chemical Nameavapritinib
Dosage FormTablet (oral; 100 mg, 200 mg, 300 mg)
Drug ClassKinase inhibitors
CompanyBlueprint Medicines
Approval Year2020


  • Ayvakit is indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ayvakit (avapritinib) Prescribing Information2020Blueprint Medicines